false 0001610820 A1 0001610820 2025-02-12 2025-02-12 0001610820 BCTX:CommonSharesNoParValueMember 2025-02-12 2025-02-12 0001610820 BCTX:WarrantsToPurchaseCommonSharesNoParValueMember 2025-02-12 2025-02-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 12, 2025

 

BRIACELL THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

 

British Columbia   47-1099599

(State or other jurisdiction

of incorporation or organization)

  

(I.R.S. Employer

Identification No.)

     

Suite 300 - 235 15th Street

West Vancouver, BC V7T 2X1

   V7T 2X1
(Address of principal executive offices)   (Zip Code)

 

(604) 921-1810

(Registrant’s telephone number, including area code)

 

Commission File No. 001-40101

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered under Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, no par value   BCTX   The Nasdaq Stock Market LLC
Warrants to purchase common shares, no par value   BCTXW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

As previously disclosed, on August 22, 2024, BriaCell Therapeutics Corp. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common shares for the prior 30 consecutive business days, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

 

On February 12, 2025, the Company received written notice from the Staff informing the Company that it has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BRIACELL THERAPEUTICS CORP.
   
  /s/ William V. Williams
February 13, 2025 William V. Williams
  President and Chief Executive Officer

 

 

 

v3.25.0.1
Cover
Feb. 12, 2025
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 12, 2025
Entity File Number 001-40101
Entity Registrant Name BRIACELL THERAPEUTICS CORP.
Entity Central Index Key 0001610820
Entity Tax Identification Number 47-1099599
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 300 - 235 15th Street
Entity Address, City or Town West Vancouver
Entity Address, State or Province BC
Entity Address, Postal Zip Code V7T 2X1
City Area Code (604)
Local Phone Number 921-1810
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Shares, no par value  
Title of 12(b) Security Common Shares, no par value
Trading Symbol BCTX
Security Exchange Name NASDAQ
Warrants to purchase common shares, no par value  
Title of 12(b) Security Warrants to purchase common shares, no par value
Trading Symbol BCTXW
Security Exchange Name NASDAQ
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more BriaCell Therapeutics Charts.
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more BriaCell Therapeutics Charts.